Why Early Cholangiocarcinoma Detection is Critical 

What is CCA?

Cholangiocarcinoma (CCA), or bile duct cancer, is the most common cancer in PSC and the leading cause of PSC-related mortality.

  • People with PSC face an annual CCA risk of 0.2%–1.5% and a lifetime risk of up to 20%, with the highest risk occurring in the first year after diagnosis.
  • Unlike other liver cancers, CCA in PSC can occur regardless of fibrosis stage, and is largely due to chronic inflammation of the cholangiocytes (bile duct cells) due to immune-mediated mechanisms and bile acid toxicity associated with cholestasis.
  • Lower‑risk groups include small‑duct PSC, PSC‑AIH overlap, and pediatric PSC.

Why does CCA Matter in PSC?

People with PSC have a 400‑fold higher risk of CCA than the general population, and this high risk profoundly shapes the lived experience of PSC. Across multiple large surveys conducted by PSC Partners and in the FDA‑sponsored Patient‑Focused Drug Development Forum, fear of CCA consistently emerged as one of the most important concerns.

Patients describe “existential anxiety” beginning at diagnosis, driven by the unpredictability of cancer and the lack of reliable early‑detection tools. Annual MRCP (MRI of the liver and bile ducts) and follow‑up procedures create significant “scanxiety,” along with physical and emotional burden. In the PSC Partners ROADMAP process involving more than 500 patients, early detection of CCA was identified as a top research priority.

Despite the high stakes, only 51% of patients report that their clinicians proactively discuss CCA risk or surveillance with them during appointments. Many turn to the internet for information, often encountering inconsistent or frightening content without clinical context. This communication gap amplifies uncertainty, distress, and feelings of isolation.

Even with current surveillance tools performing suboptimally, patients overwhelmingly express a desire for regular, informed monitoring, because it provides a sense of control over an otherwise unpredictable disease.

Current Diagnosis Standard & Treatments

The current recommendations for PSC-CCA surveillance in the US involve annual MRCP supplemented by blood serum CA 19-9 testing, but early‑stage detection remains limited. The treatment of CCA in PSC largely depends on when the malignancy is diagnosed and includes surgical resection, chemotherapy and/or liver transplantation depending on the location and stage of the lesion. Even with intervention, the outcomes remain poor with a median survival of less than 1 year, with recurrence of the tumors as high as 70% after resection or transplant.

Limitations of Current Surveillance

Surveillance for CCA in PSC is challenging, and major guidelines lack consensus.

  • MRCP sensitivity for early disease can be as low as 32%, largely because benign and malignant strictures often appear similar.
  • CA 19‑9 may help but is prone to false positives during inflammation and may be absent even when cancer is present.
  • Prospective studies have not shown that current tools reliably detect CCA early enough to improve survival.

Emerging Diagnostics

New technologies are advancing the possibility of earlier, more accurate detection. These include:

  • Liquid biopsy (ctDNA, microRNA)
  • DNA methylation assays
  • AI‑enhanced MRI

A novel metabolomic blood test is currently in development demonstrating early detection specificity and sensitivity greater than 85%. PSC Partners is supporting this project through the International Collaborative Research Network (ICRN) process as part of its broader commitment to advancing research that improves outcomes for people with PSC.